Description
Product Review:
Regenovue Sub-Q is a powerful and thick dermal filler that can decrease the look of even very severe facial wrinkles and folds. Regenovue Sub-Q is considered to be the most vicious and dense among other products in the line. The product has volumizing qualities and is ideal for adding volume to the face and reducing the look of deep wrinkles. Regenovue Sub-Q will help to define cheeks and cheekbones, giving you a healthier overall look. It can also be used for correcting folds and wrinkles in the face.
Treatment Areas:
Cheeks: Enhances volume and contours for a more youthful appearance.
Chin: Augments and reshapes to improve facial harmony and balance.
Jawline: Defines and contours the jawline for a more sculpted look.
Temples: Adds volume to hollowed or sunken temples for a refreshed appearance.
Nasolabial Folds: Softens and smoothens the lines that run from the nose to the corners of the mouth.
Marionette Lines: Diminishes the appearance of lines that extend from the corners of the mouth downward.
The Benefits of Regenovue Fine Plus include:
Regenovue Sub-Q is designed to address a variety of aesthetic concerns, including the elimination of deep wrinkles, augmentation of cheekbones and lips, correction of facial and nasal contours, and enhancement of lip volume.
The noticeable results of Regenovue Sub-Q treatment are evident immediately after the procedure. These effects can last for up to 18 months, providing long-lasting improvement in the treated areas.
The hyaluronic acid in Regenovue Sub-Q not only delivers visible enhancement but also promotes skin cell regeneration. By providing additional hydration and skin barrier protection, hyaluronic acid fosters healthier cells and a more radiant complexion.
Furthermore, hyaluronic acid contributes to smoother skin texture, resulting in a silkier and more even appearance. This improvement is not only visible but also tangible, as the skin becomes noticeably smoother to the touch.
Box Contents:
1 X 1.1ML Per Pack
Reviews
There are no reviews yet.